Therapeutic mRNA1

Therapeutic mRNA1 is a discovery-stage mRNA-based therapeutic candidate being developed by ME Therapeutics. The program is part of the company's 'Myeloid Tuning' strategy, which focuses on modulating the activity of suppressive myeloid cells, such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), to enhance anti-tumor immunity. While the specific molecular target and primary indication have not been publicly disclosed, the asset leverages mRNA technology to potentially express therapeutic proteins or cytokines intended to reprogram the tumor microenvironment. As of early 2025, the program remains in the discovery phase.